These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 18444262)

  • 41. Overcoming further challenges in the pharma/biotech industry: 2007 update.
    Graul AI; Cruces E; Revel L; Serradell N; Rosa E
    Drug News Perspect; 2008; 21(1):44-58. PubMed ID: 18301809
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Profiles of four top biotech companies in India.
    Suresh N; Rao ChS
    Biotechnol J; 2009 Mar; 4(3):295-300. PubMed ID: 19296435
    [No Abstract]   [Full Text] [Related]  

  • 43. Arnold Demain.
    Demain A
    Nat Biotechnol; 2011 Mar; 29(3):193. PubMed ID: 21390012
    [No Abstract]   [Full Text] [Related]  

  • 44. Rational optimization of proteins as drugs: a new era of 'medicinal biology'.
    Szymkowski DE
    Drug Discov Today; 2004 May; 9(9):381-3. PubMed ID: 15081952
    [No Abstract]   [Full Text] [Related]  

  • 45. Science and commerce. Chemists for hire: have flask, will travel.
    Alper J
    Science; 2001 Aug; 293(5533):1249-51. PubMed ID: 11509708
    [No Abstract]   [Full Text] [Related]  

  • 46. Europe caught in innovation quagmire.
    Mitchell P
    Nat Biotechnol; 2005 Sep; 23(9):1029. PubMed ID: 16151378
    [No Abstract]   [Full Text] [Related]  

  • 47. New Zealand: unique biodiversity and world-class science converge.
    Boalch C
    Drug Discov Today; 2006 Aug; 11(15-16):677-80. PubMed ID: 16846794
    [No Abstract]   [Full Text] [Related]  

  • 48. The business of making vaccines.
    Sheridan C
    Nat Biotechnol; 2005 Nov; 23(11):1359-66. PubMed ID: 16273061
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV vaccine developers battle on, despite high-profile failures.
    Ledford H
    Nat Biotechnol; 2008 Jun; 26(6):591-2. PubMed ID: 18536659
    [No Abstract]   [Full Text] [Related]  

  • 50. Biotech slumps in Q1.
    Lawrence S
    Nat Biotechnol; 2008 May; 26(5):486. PubMed ID: 18464769
    [No Abstract]   [Full Text] [Related]  

  • 51. On being a professional mutant.
    Saberwal G
    Nat Biotechnol; 2014 Jan; 32(1):106-7. PubMed ID: 24406936
    [No Abstract]   [Full Text] [Related]  

  • 52. A testing approach based on tiny doses still awaits big results.
    Coombs A
    Nat Med; 2008 Aug; 14(8):796. PubMed ID: 18685584
    [No Abstract]   [Full Text] [Related]  

  • 53. Designs that enrich lives.
    Link A; Stark H
    Arch Pharm (Weinheim); 2007 Oct; 340(10):509-10. PubMed ID: 17912676
    [No Abstract]   [Full Text] [Related]  

  • 54. Making it in the biotech business.
    Gewin V
    Nature; 2005 May; 435(7038):124-5. PubMed ID: 15875029
    [No Abstract]   [Full Text] [Related]  

  • 55. The art of bioprocessing.
    Jungbauer A
    Biotechnol J; 2006 Feb; 1(2):111. PubMed ID: 16892235
    [No Abstract]   [Full Text] [Related]  

  • 56. Advice for partnering with pharma.
    Howard K
    Nat Biotechnol; 2004 Nov; 22(11):1477-9. PubMed ID: 15586421
    [No Abstract]   [Full Text] [Related]  

  • 57. Biotech firms pin hopes on defence.
    Pearson H
    Nature; 2003 Apr; 422(6934):790. PubMed ID: 12712154
    [No Abstract]   [Full Text] [Related]  

  • 58. Signal transduction as a drug-discovery platform.
    Nat Biotechnol; 2000 Oct; 18 Suppl():IT37-9. PubMed ID: 11221714
    [No Abstract]   [Full Text] [Related]  

  • 59. Signal transduction as a drug-discovery platform.
    Persidis A
    Nat Biotechnol; 1998 Nov; 16(11):1082-3. PubMed ID: 9831041
    [No Abstract]   [Full Text] [Related]  

  • 60. Advancing in the face of conventional wisdom.
    Lanzara R
    Drug Discov Today; 2004 Feb; 9(3):110-1. PubMed ID: 14960386
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.